Group
ROS1 targeting TKI
The data below refer to patients treated with ROS1 targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Taletrectinib
No data